瑞舒伐他汀对急性心肌梗死PCI术后患者血清cTnI、CK-MB、Myo及血小板活化功能、炎性因子水平的影响  

Effects of Rosuvastatin on serum cTnI,CK-MB,Myo,platelet activation and inflammatory factor with acute myocardial infarction after PCI

作　　者：余波[1] 艾芬[1] 杨飞燕[1] 

机构地区：[1]华中科技大学同济医学院附属武汉中心医院急诊科,湖北武汉430000

出　　处：《海南医学院学报》2016年第19期2269-2272,共4页Journal of Hainan Medical University

基　　金：武汉市医学科学研究项目(WX11C10)~~

摘　　要：目的：探讨瑞舒伐他汀对急性心肌梗死经皮冠状动脉介入（percutaneouscoronaryintervention，PCI）术后患者血清肌钙蛋白I（cTnI）、肌酸激酶同工酶（CK-MB）、肌红蛋白（Myo）及血小板活化功能、炎性因子水平的影响。方法：选择2013年1月～2016年1月在我院收治的90例急性ST段抬高型心肌梗死患者，随机分为对照组和试验组，各45例。对照组于PCI术前给予常规治疗，试验组于PCI术前常规治疗的基础上给予瑞舒伐他汀。检测并比较两组治疗前后血清cTnI、CK-MB、Myo及血小板活化功能指标，包括溶酶体膜糖蛋白（CD63）、血小板a颗粒表面膜糖蛋白（CD62p）、单核细胞血小板聚集体（MPA）以及血清炎性因子水平，包括肿瘤坏死因子α（TNF-α）、超敏C反应蛋白（hs-cRP）、白细胞介素10（IL-10）。结果：治疗前，两组血清cTnI、CK-MB及Myo水平比较差异无统计学意义（P〉0．05）；治疗后，对照组血清cTnI、CK-MB及Myo水平均明显高于治疗前，同时试验组血清cTnI、CK-MB及Myo水平均明显低于对照组，差异均具有统计学意义（P〈0．05）。治疗前，两组CD63、CD62P及MPA含量比较差异无统计学意义（P〉0．05）；治疗后，两组CD63、CD62P及MPA含量均明显低于治疗前，同时试验组CD63、CD62P及MPA含量均明显低于对照组，差异均具有统计学意义（P〈0．05）。治疗前，两组血清TNF-α、hs-CRP及IL-10水平比较差异无统计学意义（P〉0．05）；治疗后，对照组血清TNF-α、hs-CRP及IL-10水平均明显高于治疗前，同时试验组血清TNF-α、hs-CRP及IL-10水平均明显低于对照组，差异均具有统计学意义（P〈0．05）。结论：急性心肌梗死患者PCI术前短期给予瑞舒伐他汀能够明显减轻患者心肌损伤、抑制血小板活化以及降低血清炎性因子水平，具有保护心肌的作用，对急性心肌梗死的治疗具有积极作用。Objective.. To study the effect of rosuvastatin on serum cTnI, CK-MB, Myo, platelet activation and inflam- matory factor with acute myocardial infarction after percutaneous coronary intervention（PCI）. Methods： A total of 90 patients with acute myocardial infarction in our hospital from January 2013 to January 2016 were enrolled in this study. The subjects were divided into control group （n =45） and treatment group （n =45） randomly. The control group was treated with routine therapy before PCI, the treatment group were treated with rosuvastatin combined with routine therapy before PCI. The serum levels of cTnI, CK-MB, Myo, CD63, CD62p, MPA, TNF-a, hs-CRP and IL-10 of the two groups before and after treatment were compared. Results： There were no significantly differences of the levels of serum eTnI, CK-MB and Myo of the two groups before treatment （P〉0.05）. The levels of serum cTnI, CK-MB and Myo of the control group after treatment were sig- nificantly lower than before treatment （P 〈 0.05）, and that of treatment were significantly lower than control group （P〈 0.05）.There were no significantly differences of the levels of CD63, CD62p and MPA of the two groups before treatment （P〉 0.05）. The levels of CD63, CD62p and MPA of the two groups after treatment were significantly lower than before treatment （P 〈0.05）, and that of treatment were significantly lower than control group （P 〈 0.05）. There were no significantly differ- ences of the levels of serum TNF-α, hs-CRP and IL-10 of the two groups before treatment （P〉0.05）. The levels of serum TNF-α, hs-CRP and IL-10 of the control group after treatment were significantly lower than before treatment （P〈0.05）, and that of treatment were significantly lower than control group （P 〈0.05）. Conclusions： Rosuvastatin can effective relieve the myocardial injury of acute myocardial infarction patients treated by PCI, reduce the inflammatory cytokines levels, inhibit plate- let activation and protect myoca

关 键 词：瑞舒伐他汀 急性心肌梗死 经皮冠状动脉介入治疗 血小板活化功能 炎性因子 

分 类 号：R542.22[医药卫生—心血管疾病]